StockData
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. (ACRS) stock

ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30155% above fair value
$3.38−0.23 (-6.24%)

Close on Nov 17, 2026Market cap $497.53MP/E –Yield –

Aclaris Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Aclaris Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $63.34M, up 66.6% year over year. For fiscal 2025 it was $52.65M, up 56.7% from the year before. Over ten years it grew 13.1% a year on average. The highest annual figure on record is $98.38M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$52.65M+56.7%
FY2024Dec 31, 2024$33.59M-65.9%
FY2023Dec 31, 2023$98.38M+26.4%
FY2022Dec 31, 2022$77.81M+77.6%
FY2021Dec 31, 2021$43.81M+49.3%
FY2020Dec 31, 2020$29.34M-54.3%
FY2019Dec 31, 2019$64.17M+5.5%
FY2018Dec 31, 2018$60.84M+69.9%
FY2017Dec 31, 2017$35.80M+7.0%
FY2016Dec 31, 2016$33.48M+118.2%
FY2015Dec 31, 2015$15.34M+135.7%
FY2014Dec 31, 2014$6.51M+86.6%
FY2013Dec 31, 2013$3.49M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$18.07M+57.8%
Q1 FY2026Mar 31, 2026$15.66M+35.2%
Q4 FY2025Dec 31, 2025$16.58M+83.7%
Q3 FY2025Sep 30, 2025$13.03M+118.7%
Q2 FY2025Jun 30, 2025$11.45M+30.7%
Q1 FY2025Mar 31, 2025$11.58M+17.7%
Q4 FY2024Dec 31, 2024$9.03M-66.1%
Q3 FY2024Sep 30, 2024$5.96M-75.1%
Q2 FY2024Jun 30, 2024$8.76M-65.3%
Q1 FY2024Mar 31, 2024$9.85M-56.4%
Q4 FY2023Dec 31, 2023$26.65M+26.5%
Q3 FY2023Sep 30, 2023$23.88M+0.9%
Q2 FY2023Jun 30, 2023$25.28M+34.6%
Q1 FY2023Mar 31, 2023$22.59M+57.9%
Q4 FY2022Dec 31, 2022$21.07M+49.4%
Q3 FY2022Sep 30, 2022$23.66M+69.3%
Q2 FY2022Jun 30, 2022$18.78M+137.8%
Q1 FY2022Mar 31, 2022$14.31M+82.5%
Q4 FY2021Dec 31, 2021$14.10M+57.5%
Q3 FY2021Sep 30, 2021$13.98M+124.0%
Q2 FY2021Jun 30, 2021$7.90M+22.1%
Q1 FY2021Mar 31, 2021$7.84M+2.1%
Q4 FY2020Dec 31, 2020$8.96M-17.3%
Q3 FY2020Sep 30, 2020$6.24M-61.4%
Q2 FY2020Jun 30, 2020$6.47M-63.1%
Q1 FY2020Mar 31, 2020$7.68M-60.9%
Q4 FY2019Dec 31, 2019$10.83M-44.1%
Q3 FY2019Sep 30, 2019$16.18M+6.5%
Q2 FY2019Jun 30, 2019$17.52M+25.3%
Q1 FY2019Mar 31, 2019$19.64M+44.4%
Q4 FY2018Dec 31, 2018$19.36M+110.4%
Q3 FY2018Sep 30, 2018$15.19M+39.8%
Q2 FY2018Jun 30, 2018$13.98M+75.6%
Q1 FY2018Mar 31, 2018$13.61M+75.1%
Q4 FY2017Dec 31, 2017$9.20M+32.6%
Q3 FY2017Sep 30, 2017$10.86M+51.7%
Q2 FY2017Jun 30, 2017$7.97M–
Q1 FY2017Mar 31, 2017$7.77M–
Q4 FY2016Dec 31, 2016$6.94M–
Q3 FY2016Sep 30, 2016$7.16M–

More Aclaris Therapeutics figures

See a number that looks wrong?